Sequence: Stearyl-AGYLLGKLLOOLAAAALOOLL-NH2
| Experiment Id | EXP001409 |
|---|---|
| Paper | Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simula |
| Peptide | PepFect 14 (PF14) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Encoded by peptide:siRNA molar ratio (MR); typical MR30–MR40 |
| Rna Concentration | Not explicitly stated for Jurkat; described as efficient knockdown in Supplementary Fig. 1 |
| Mixing Ratio | PF14:siRNA molar ratio (MR) 20–40 screened; best MR depends on serum conditions |
| Formulation Format | Noncovalent PF14/siRNA nanocomplex |
| Formulation Components | PF14 + siRNA (noncovalent nanocomplex; molar ratio MR ~30–40 depending on condition) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Jurkat (human T lymphocyte suspension) |
| Animal Model | |
| Administration Route | |
| Output Type | HPRT1 mRNA knockdown (qRT-PCR) |
| Output Value | |
| Output Units | |
| Output Notes | Efficient HPRT1 silencing in Jurkat cells (hard-to-transfect) reported in Supplementary Fig. 1. |
| Toxicity Notes | |
| Curation Notes |